Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant Enterobacterales Bacteremia in Patients With Hematologic Malignancies.

Authors

Hyeon Mu Jang, Seunghee Baek, So Yun Lim, Seongman Bae, Hyunkyung Park, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Je-Hwan Lee, Sung-Han Kim

Published in

Journal of Korean medical science. Volume 41. Issue 35. Pages e228. Sep 07, 2026. Epub Sep 07, 2026.

Abstract

Until recent introduction of ceftazidime/avibactam (CAZ-AVI) to Korean hospitals in October 2023, alternative antibiotics had been used to treat carbapenem-resistant Enterobacterales (CRE) infection such as high-dose meropenem combination therapy with amikacin, tigecycline, and/or colistin. To compare the outcome of CRE bacteremia between CAZ-AVI (study group) and alternative antibiotics (comparator group) before/after the introduction of CAZ-AVI.
We retrospectively reviewed the adult patients with hematologic malignancy who had CRE bacteremia between January 2020 and July 2024.
A total of 85 patients with CRE bacteremia were analyzed including 25 with CAZ-AVI and 60 with alternative antibiotics. In a time-dependent multivariable Cox model for negative conversion of bacteremia, CAZ-AVI (hazard ratio [HR], 2.475; 95% confidence interval [CI], 1.493-4.102; P < 0.001) and Klebsiella pneumoniae carbapenemase [KPC] (HR, 0.490; 95% CI, 0.296-0.810; P = 0.005) was independently associated with rapid negative conversion. CAZ-AVI was associated with rapid negative conversion of bacteremia in the inverse probability of treatment weighting (IPTW) analysis (HR, 3.030; 95% CI, 1.818-5.263; P < 0.001). In a time-dependent multivariable Cox model, CAZ-AVI was the only independent predictor for 30-day mortality (HR, 0.295; 95% CI, 0.087-0.996; P = 0.049), although CAZ-AVI did not reach any statistical significance for 30-day mortality (HR, 0.513; 95% CI, 0.146-1.804; P = 0.298) in IPTW analysis.
CAZ-AVI showed higher rapid negative conversion for CRE bacteremia in patients with hematologic malignancy, compared to the alternative antibiotics.

PMID:
42708480
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.